148 related articles for article (PubMed ID: 24999075)
1. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; ; Obermair A
Contemp Clin Trials; 2014 Sep; 39(1):14-21. PubMed ID: 24999075
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
3. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M; Robledo KP; Gebski V; Armes JE; Alizart M; Cummings M; Chen C; Leung Y; Sykes P; McNally O; Oehler MK; Walker G; Garrett A; Tang A; Land R; Nicklin JL; Chetty N; Perrin LC; Hoet G; Sowden K; Eva L; Tristram A; Obermair A
Gynecol Oncol; 2021 Apr; 161(1):143-151. PubMed ID: 33762086
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
6. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
[TBL] [Abstract][Full Text] [Related]
7. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
Baker WD; Pierce SR; Mills AM; Gehrig PA; Duska LR
Gynecol Oncol; 2017 Jul; 146(1):34-38. PubMed ID: 28427775
[TBL] [Abstract][Full Text] [Related]
8. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
9. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characteristics and treatment features of women with the incidental diagnosis of endometrial adenocarcinoma during infertility follow-up in Ankara, Turkey.
Gungor T; Cetinkaya N; Yalcin H; Zergeroglu S; Erkaya S
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):309-13. PubMed ID: 27343306
[TBL] [Abstract][Full Text] [Related]
11. Conservative treatment of early endometrial cancer: preliminary results of a pilot study.
Laurelli G; Di Vagno G; Scaffa C; Losito S; Del Giudice M; Greggi S
Gynecol Oncol; 2011 Jan; 120(1):43-6. PubMed ID: 21040953
[TBL] [Abstract][Full Text] [Related]
12. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy.
Bourdrez P; Bongers MY; Mol BW
Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.
Ravi RD; Kalra J; Srinivasan R; Bagga R; Jain V; Suri V; Sachdeva N
Asian Pac J Cancer Prev; 2021 Mar; 22(3):983-989. PubMed ID: 33773565
[TBL] [Abstract][Full Text] [Related]
14. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management.
Nwanodi O
Healthcare (Basel); 2017 Jul; 5(3):. PubMed ID: 28698465
[TBL] [Abstract][Full Text] [Related]
15. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
[TBL] [Abstract][Full Text] [Related]
16. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding.
Crosignani PG; Vercellini P; Mosconi P; Oldani S; Cortesi I; De Giorgi O
Obstet Gynecol; 1997 Aug; 90(2):257-63. PubMed ID: 9241305
[TBL] [Abstract][Full Text] [Related]
17. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
18. Conservative hysteroscopic treatment of stage I well differentiated endometrial cancer in patients with high surgical risk: a pilot study.
Casadio P; Guasina F; Talamo MR; Paradisi R; Morra C; Magnarelli G; Seracchioli R
J Gynecol Oncol; 2019 Jul; 30(4):e62. PubMed ID: 31074243
[TBL] [Abstract][Full Text] [Related]
19. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
Dhar KK; NeedhiRajan T; Koslowski M; Woolas RP
Gynecol Oncol; 2005 Jun; 97(3):924-7. PubMed ID: 15943993
[TBL] [Abstract][Full Text] [Related]
20. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
